Literature DB >> 23036655

Etiology, clinical features and outcome of epilepsia partialis continua in cohort of 51 children.

Ruzica Kravljanac1, Milena Djuric, Nebojsa Jovic, Maja Djordjevic, Dragan Zamurovic, Tatjana Pekmezovic.   

Abstract

The objective of the study was to evaluate etiology, clinical characteristics and outcome in children with epilepsia partialis continua (EPC). The investigation included 51 children with EPC aged 0.2-18 years treated in the period 1993-2009. The median period from the onset of underlying disorder to EPC was 6 months (0-72 months). EPC was caused by different pathologies: inflammatory and immune-mediated (52%), metabolic (13.7%), structural brain abnormalities (11.8%), cryptogenic (7.8%), vascular (5.9%), dual (5.9%), postoperative (2%). Median duration of EPC was 15 days (1-200 days). EPC involved more frequently the right side of the body comparing to the left one. The outcome was assessed at the end of the follow up period (mean 6.5 years, ranged 0.2-16 years). Unchanged neurological status was observed in 10 (19.6%) children, neurological consequences in 33 (64.7%) children and lethal outcome in 8 (15.7%) children. The most frequent etiology in our cohort was inflammatory and immune-mediated disease of central nerve system including Rasmussen's encephalitis. The duration of EPC was prolonged, most frequently involving the right upper limb. The outcome of EPC in children was unfavorable.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23036655     DOI: 10.1016/j.eplepsyres.2012.09.003

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  3 in total

1.  Deleterious variants in TRAK1 disrupt mitochondrial movement and cause fatal encephalopathy.

Authors:  Ortal Barel; May Christine V Malicdan; Bruria Ben-Zeev; Judith Kandel; Hadass Pri-Chen; Joshi Stephen; Inês G Castro; Jeremy Metz; Osama Atawa; Sharon Moshkovitz; Esther Ganelin; Iris Barshack; Sylvie Polak-Charcon; Dvora Nass; Dina Marek-Yagel; Ninette Amariglio; Nechama Shalva; Thierry Vilboux; Carlos Ferreira; Ben Pode-Shakked; Gali Heimer; Chen Hoffmann; Tal Yardeni; Andreea Nissenkorn; Camila Avivi; Eran Eyal; Nitzan Kol; Efrat Glick Saar; Douglas C Wallace; William A Gahl; Gideon Rechavi; Michael Schrader; David M Eckmann; Yair Anikster
Journal:  Brain       Date:  2017-03-01       Impact factor: 13.501

2.  Rasmussen's encephalitis: advances in management and patient outcomes.

Authors:  Caitlin E Hoffman; Ayako Ochi; Orlando Carter Snead; Elysa Widjaja; Cynthia Hawkins; Martin Tisdal; James T Rutka
Journal:  Childs Nerv Syst       Date:  2016-01-16       Impact factor: 1.475

3.  Responsive neurostimulation for focal motor status epilepticus.

Authors:  Jimmy C Yang; Nitish M Harid; Fábio A Nascimento; Vasileios Kokkinos; Abigail Shaughnessy; Alice D Lam; M Brandon Westover; Thabele M Leslie-Mazwi; Leigh R Hochberg; Eric S Rosenthal; Andrew J Cole; Robert M Richardson; Sydney S Cash
Journal:  Ann Clin Transl Neurol       Date:  2021-05-06       Impact factor: 4.511

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.